Catalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for IMVT-1402 in Cutaneous Lupus Erythematosus. The expected timing is based on the latest available company guidance and may change.
05/20/26:- CLE PoC trial fully enrolled; topline data expected in H2 2026. 08/06/26:- CLE topline data remains expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.